A consortium of funds affiliated with Hellman & Friedman executed the disposal of approximately $1.16 billion worth of Medline Inc.'s (MDLN) Class A Common Stock on May 28, 2026. These sales were structured as part of an underwritten public offering.
The details of the transactions reveal that a total of 31,868,237 shares of Class A Common Stock were sold at a price point of $36.5375 per share. This sale price was determined by subtracting an underwriting discount of $0.4625 from the secondary public offering price of $37.00 per share. While this offering price represents a premium when compared to the current market valuation, some analysis suggests that the healthcare equipment supplier may still be undervalued, noting that the stock trades below its Fair Value and positioning it as one of the most undervalued opportunities within its sector.
Details of Reported Sales
The transactions involved several specific reporting entities:
- Mend Investment Holdings I, L.P. disposed of 17,947,337 shares, leaving the entity with a remaining holding of 228,840 shares.
- Hellman & Friedman Capital Partners X (Parallel), L.P. sold 11,904,646 shares, resulting in an ownership balance of 62,591,526 shares following the disposition.
- HFCP X (Parallel - A), L.P. accounted for the sale of 1,262,726 shares, maintaining a subsequent holding of 6,519,062 shares.
- Mend Partners II, L.P. sold 753,528 shares, retaining 3,422,699 shares.
In-Kind Distributions Follow the Sales
On the same date of the major sales, several of these involved entities also completed in-kind distributions of Class A Common Stock to their respective ultimate partners and shareholders. It is important to note that these specific transfers were not cash sales. The distribution details included:
- Hellman & Friedman Capital Partners X (Parallel), L.P. distributed 1,536,907 shares.
- Mend Investment Holdings I, L.P. distributed 209,530 shares.
- HFCP X (Parallel - A), L.P. distributed 141,364 shares.
Corporate Structure and Ownership Context
The reporting owners, which encompass various Hellman & Friedman funds, are identified as holding a ten percent stake in Medline Inc. These entities explicitly disclaim beneficial ownership of the reported securities, reserving such claim only to the extent of their pecuniary interest. Furthermore, voting and investment discretion over these specific securities are managed by a three-member board of directors representing H&F Corporate Investors X, Ltd.
Recent Company Developments
In other recent corporate news, Medline Inc. had previously completed a secondary offering involving 72.6 million shares of Class A common stock. This transaction was priced at $37 per share and saw the sale executed by stockholders affiliated with Blackstone Inc., Hellman & Friedman LLC, and the Abu Dhabi Investment Authority. Reports indicated that this particular offering was oversubscribed, meaning the demand for the available shares exceeded the number of shares offered.
Separately, Medline’s Canadian division has successfully entered into its inaugural Prime Vendor agreement in Canada with Mohawk Medbuy. This significant agreement will enable Medline Canada to manage both warehouse and supply chain logistics services for hospitals located in Southwestern Ontario.
On the financial analysis front, Barclays adjusted its price target for Medline. The firm lowered its previous target from $50 down to $45, while simultaneously maintaining an Overweight rating on the stock. In its rationale, Barclays cited material input costs, specifically mentioning fuel, as a key factor influencing future financial performance.
The analysis of institutional activity and recent corporate transactions highlights significant movement in the healthcare equipment sector, suggesting ongoing valuation considerations despite large-scale sales.